Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

Argenx’s $2.2 billion acquisition of Forte Biosciences marks a strategic expansion of its immunology pipeline, signaling a growing trend of mid-cap biotechs acting as active acquirers in the industry. Beyond deal-making, the integration of generative AI into biopharma R&D workflows is reshaping the tech stack, with companies like Anthropic, NVIDIA, and OpenAI providing specialized tools that demand high-level scientific expertise for effective application. While AI models offer significant potential for accelerating drug discovery, the competitive advantage remains rooted in proprietary data and the ability to design specific, agentic workflows. Meanwhile, the first-half clinical catalyst scorecard reveals a strong performance across RNA-based modalities, particularly with promising functional cures for chronic hepatitis B and advancements in antisense and siRNA programs, setting a high bar for upcoming regulatory milestones through the end of 2026.